was read the article
array:24 [ "pii" => "S2173574312001323" "issn" => "21735743" "doi" => "10.1016/j.reumae.2012.08.001" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "444" "copyright" => "Elsevier España, S.L.. All rights reserved" "copyrightAnyo" => "2011" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Reumatol Clin. 2012;8:270-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 29166 "formatos" => array:3 [ "EPUB" => 84 "HTML" => 27596 "PDF" => 1486 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X12000903" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2012.02.006" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "444" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Reumatol Clin. 2012;8:270-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 73948 "formatos" => array:3 [ "EPUB" => 198 "HTML" => 60185 "PDF" => 13565 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Raynaud, úlceras digitales y calcinosis en esclerodermia" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "270" "paginaFinal" => "277" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Raynaud, digital ulcers and calcinosis in scleroderma" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alejandro Nitsche" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Alejandro" "apellidos" => "Nitsche" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574312001323" "doi" => "10.1016/j.reumae.2012.08.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574312001323?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X12000903?idApp=UINPBA00004M" "url" => "/1699258X/0000000800000005/v1_201305061926/S1699258X12000903/v1_201305061926/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574312000743" "issn" => "21735743" "doi" => "10.1016/j.reumae.2011.11.010" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "401" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2012;8:278-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 6510 "formatos" => array:3 [ "EPUB" => 54 "HTML" => 5639 "PDF" => 817 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case Report</span>" "titulo" => "Cushings Disease as a Cause of Severe Osteoporosis: A Clinical Challenge" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "278" "paginaFinal" => "279" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad de Cushing como causa de osteoporosis grave. Un reto clínico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1320 "Ancho" => 2167 "Tamanyo" => 176158 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">(A) Severe stage 3 dorsal vertebral fractures (arrows), moderate stage 1–2 dorsal fracture. (B) Fracture of the upper sternal body.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Nadia Abdel-Kader, Mario H. Cardiel, Victoria Navarro Compan, Juan Piedra Priego, Ana González" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Nadia" "apellidos" => "Abdel-Kader" ] 1 => array:2 [ "nombre" => "Mario H." "apellidos" => "Cardiel" ] 2 => array:2 [ "nombre" => "Victoria" "apellidos" => "Navarro Compan" ] 3 => array:2 [ "nombre" => "Juan" "apellidos" => "Piedra Priego" ] 4 => array:2 [ "nombre" => "Ana" "apellidos" => "González" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X11003718" "doi" => "10.1016/j.reuma.2011.11.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X11003718?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574312000743?idApp=UINPBA00004M" "url" => "/21735743/0000000800000005/v1_201305061645/S2173574312000743/v1_201305061645/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173574312001335" "issn" => "21735743" "doi" => "10.1016/j.reumae.2012.08.002" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "428" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Reumatol Clin. 2012;8:263-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3909 "formatos" => array:3 [ "EPUB" => 56 "HTML" => 3102 "PDF" => 751 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review Article</span>" "titulo" => "New Targets in Systemic Lupus (Part 2/2)" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "263" "paginaFinal" => "269" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nuevas dianas terapéuticas en el lupus sistémico (parte 2/2)" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Walter A. Sifuentes Giraldo, María J. García Villanueva, Alina L. Boteanu, Ana Lois Iglesias, Antonio C. Zea Mendoza" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Walter A." "apellidos" => "Sifuentes Giraldo" ] 1 => array:2 [ "nombre" => "María J." "apellidos" => "García Villanueva" ] 2 => array:2 [ "nombre" => "Alina L." "apellidos" => "Boteanu" ] 3 => array:2 [ "nombre" => "Ana" "apellidos" => "Lois Iglesias" ] 4 => array:2 [ "nombre" => "Antonio C." "apellidos" => "Zea Mendoza" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X12000605" "doi" => "10.1016/j.reuma.2012.01.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X12000605?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574312001335?idApp=UINPBA00004M" "url" => "/21735743/0000000800000005/v1_201305061645/S2173574312001335/v1_201305061645/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review Article</span>" "titulo" => "Raynaud, Digital Ulcers and Calcinosis in Scleroderma" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "270" "paginaFinal" => "277" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Alejandro Nitsche" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Alejandro" "apellidos" => "Nitsche" "email" => array:1 [ 0 => "alejandro.nitsche@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Specialist in rheumatology, Servicio de Reumatología, Hospital Alemán; Consultorio de Raynaud, Esclerodermia e Hipertensión Arterial Pulmonar, Sanatorio San José, Ciudad Autónoma de Buenos Aires, Argentina" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Raynaud, úlceras digitales y calcinosis en esclerodermia" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Despite scleroderma being a rare disease, it is common for rheumatologists in daily practice to receive referrals of patients with Raynaud's phenomenon and underlying systemic sclerosis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Raynaud's phenomenon may precede by more than 10 years the clinical manifestations of the disease. Because these characteristics of scleroderma overlap with other connective tissue diseases, diagnostic delay is a problem. An early referral on the basis of questioning, physical examination, capillaroscopy and laboratory guide are of paramount importance for diagnosis.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–3</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The purpose of this update is to analyze the pathogenic mechanisms and the impact on quality of life of patients with Raynaud's phenomenon, digital ulcers and calcinosis, as well as its possible treatments, with information from the literature, published guidelines and experience from observational studies.</p><p id="par0020" class="elsevierStylePara elsevierViewall">We must not forget the difficulties reported by several authors at the time of incorporating patients with scleroderma in various controlled studies.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Finally, treating physicians, within the scope of their practice, may apply the knowledge in the difficult management of these patients.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6–9</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Pathophysiology</span><p id="par0030" class="elsevierStylePara elsevierViewall">Scleroderma is a complex autoimmune disease that potentially affects all organ systems.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The pathophysiology involves several cell lines, such as endothelium, fibroblasts, lymphocytes and their soluble mediators. These cells set the tone for an early vascular phase with an inflammatory infiltrate and finally fibrosis.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> The vascular phase begins in the endothelium of small vessels throughout the body, although the primary event that triggers endothelial damage is unknown. Tissue hypoxia is one of the primary events that modify vascular tone.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Nitric oxide, prostacyclin and endothelin regulate the vascular tone our body. Both nitric oxide and prostacyclin are potent endogenous vasodilators that also have antiproliferative action. In contrast, the endothelin system acts as a counterweight for vascular tone, being a potent vasoconstrictor. Endothelin 1 (ET1) has 10 times the angiotensin<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> vasoconstrictor effect.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Endothelial cells are involved in vascular homeostasis by regulating both muscle tone and cell proliferation. Vasoconstriction is caused by an imbalance of the mediators listed above. Cellular inflammation and perivascular infiltrates with complement deposition and release of proinflammatory mediators complete the picture.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Endothelins are small peptides of 21 amino acids with a potent vasoconstrictor effect. The 3 isoforms of endothelins, ET1, ET2 and ET3, are produced by various cells.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> Among them, endothelial cells and vascular smooth muscle, distributed in all organs, play a dominant role in the pathogenesis of scleroderma. ET2 and ET3 are distributed differently in kidney, intestine, placenta, uterus, myocardium, brain and to a lesser extent in the lung.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">From the viewpoint of pathogenesis, ET1's role explains the different events in the endothelial phase. ET1 is synthesized in endothelial cells and to a lesser extent in vascular smooth muscle cells. It is also synthesized in mesangial cells, liver cells and cells of the central nervous system.</p><p id="par0060" class="elsevierStylePara elsevierViewall">The ET1 prehormone is activated by the endothelin converting enzyme, and its biosynthesis stimulated by mechanisms such as hypoxia, metabolic disorders and various procoagulants<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11–14</span></a> disorders. It is increased in clinical situations, such as hypertension, atherosclerosis, heart failure and renal failure.</p><p id="par0065" class="elsevierStylePara elsevierViewall">In addition to its potent vasoconstrictor, ET1 has proinflammatory action, promoting cell proliferation and fibrosis. The action of endothelin is genetically encoded by the transforming growth factor beta (TGF-beta), which, by binding to its tissue receptor overexpresses proteins called Smad, which are the genes encoding collagen. Different Smad proteins have different roles, either in the overproduction of collagen and in inhibiting the formation of collagen. This loss of balance is seen in patients with progressive systemic sclerosis.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">ET1 exerts its action through two receptors: ET1 A and ET1 B, both different and complementary in action.</p><p id="par0075" class="elsevierStylePara elsevierViewall">The ET1 A receptor is located on smooth muscle cells of pulmonary vessels and favors proliferation,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> vasoconstrictor action and activity.</p><p id="par0080" class="elsevierStylePara elsevierViewall">The ET1 B receptor is located on endothelial cells and to a lesser extent in smooth muscle cells. The action on this receptor varies according to its location: in endothelial cells its vasodilatory action is mediated by the release of nitric oxide and prostacyclin, contributing to the purification of ET1 and inhibition of platelet aggregation. But in the smooth muscle cells, action on the B receptor is vasoconstriction with proliferation and fibrosis.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">It has been shown that, in general in scleroderma, both diffuse and limited, serum endothelin levels are increased significantly. This excess endothelin vasoconstriction creates an imbalance between initial and subsequent cell proliferation or remodeling. These events explain the positive correlation between increased levels of pulmonary pressures and elevated levels of endothelin. Thus the higher levels of endothelin, the higher the values of pulmonary systolic pressure. This supports the dramatic improvement in survival of patients with pulmonary arterial hypertension by blocking endothelin receptor.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Once the endothelial phase of the disease is installed, baseline hypoxia activates the overproduction of endothelin. This excess disturbs the balance of endothelin with nitric oxide and prostacyclins, generating a potent vasoconstrictor action that is not countered, establishing a vicious circle in which the unresolved tissue ischemia leads to increased vasoconstriction, release of proinflammatory cytokines and platelet aggregation as well as stimulation of fibroblast activity. The increase of platelet aggregation with endothelial proliferation and secondary thrombosis promotes remodeling.</p><p id="par0095" class="elsevierStylePara elsevierViewall">Nitric oxide and prostaglandins help maintain the vascular tone balance. Nitric oxide generated by the conversion of <span class="elsevierStyleSmallCaps">l</span>-arginine to <span class="elsevierStyleSmallCaps">l</span>-citrulline produces vasodilation, platelet antiaggregation and inhibition of cell proliferation mediated by cGMP. Prostaglandins, through the arachidonic acid pathway mediated by cAMP, produce vasodilatation with antiinflammatory action. These actions are balanced by a family of phosphodiesterases, which by inhibiting cGMP and cAMP counteract nitric oxide-mediated vasodilation and prostacyclins.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,10</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Clinical Manifestations</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Raynaud's Phenomenon</span><p id="par0100" class="elsevierStylePara elsevierViewall">Raynaud's phenomenon is a transient reversible, vasospastic phenomenon, induced by cold or stress. It occurs in fingers, toes and, less frequently, nose, ears and nipples. It may be asymmetric and not affect all fingers.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,6</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Typically, changes in skin color undergo 3 phases: initial pallor, cyanosis, and finally erythema as an expression of a compensatory vasodilatation phase. Analyzing the clinical manifestations of progressive systemic sclerosis, both diffuse and limited, Raynaud's is present in most patients.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The prevalence of Raynaud's occurs in less than 10% in the general population.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Secondary Raynaud can occur at any age, while the primary form usually refers to patients in their youth.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Digital Ulcers in Scleroderma</span><p id="par0120" class="elsevierStylePara elsevierViewall">A study of 1614 patients with digital ulcers in scleroderma highlights that defining a digital ulcer can be difficult and complex.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> This is especially important in relation to the inclusion of patients in various research protocols, in some of which digital ulcer are considered as a loss of the dermis equal to or greater than 2<span class="elsevierStyleHsp" style=""></span>mm of palmar location on the finger pads of an ischemic etiology.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,18</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">However, despite the different criteria, digital ulcers in patients with scleroderma may be simply defined as a loss of continuity in the epidermis and adjacent layers and of digital location.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,16–18</span></a></p><p id="par0130" class="elsevierStylePara elsevierViewall">By contrast, ulcer healing involves the complete re-epithelialization of the same, irrespective of pain.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Regarding digital ulcers, we must consider certain features: size, borders, bedding, exposure of tissue (bone, tendons) and presence of underlying calcinosis. An active ulcer is considered acute when its development occurs in less than 3 months, and chronic if lasting more than 6 months.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Digital ulcers in scleroderma patients can be seen in the hands and feet. So-called non-digital ulcers have also been described. Non-digital ulcers in patients with scleroderma are located on the shins, ankles, elbows and forefeet. The leg lesions are generally large and should undergo a differential diagnosis with vasculitis.</p><p id="par0145" class="elsevierStylePara elsevierViewall">The mechanism of development of digital ulcers in scleroderma is due to multiple factors which include repeated microtrauma, thinning skin, dry skin and underlying calcinosis. It is estimated that 8%–12% of ulcers have underlying calcinosis. However, prolonged digital ischemia as an expression of unresolved Raynaud's phenomenon is the most important risk factor.</p><p id="par0150" class="elsevierStylePara elsevierViewall">The clinical outcome of ulcers depends on the factors listed above. Thirty percent of patients with scleroderma and digital ulcers have a loss of soft tissue and bone. In analyzing the complications of patients with ulcers after 7 years of monitoring, digital gangrene was observed in 11%, but if the treatment fails to reverse the ischemia, virtually 100% of patients with digital ulcers suffer from gangrene afterwards.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Twelve percent of patients with ulcers require hospitalization and surgery.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,8</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall">When analyzing the different databases of patients with scleroderma, 58% develop at least one digital ulcer at some point in the disease. In 32% of cases, ulcers will become chronic and persistent.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,19</span></a> Twenty-five percent of patients with scleroderma in the rheumatology clinic have more than two digital<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> ulcers. The ulcers are observed both in patients with a diffuse cutaneous variant and in patients with a limited cutaneous variant of scleroderma.</p><p id="par0160" class="elsevierStylePara elsevierViewall">The impact on the quality of life and disability of patients with digital ulcers can objectify scleroderma through the HAQ, visual scale for pain, scale of severity of the ulcer, loss of limb function and the loss of joint function related to the ulcer.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Disability generating digital ulcers may be transient or permanent.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Calcinosis</span><p id="par0170" class="elsevierStylePara elsevierViewall">Patients with limited scleroderma most often develop calcinosis. These calcium deposits are located in soft tissues, without causing direct joint involvement, and may be small or large and usually complicated by skin ulceration and superimposed infection.</p><p id="par0175" class="elsevierStylePara elsevierViewall">The main pathophysiological mechanism for the development of calcinosis in scleroderma is tissue hypoxia.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> This decrease in perfusion is accompanied by inflammatory cell activity and macrophage activation as well as an imbalance between various mediators that cause increased calcium influx to cells.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">Patients with extensive calcinosis exhibit significant impairment of functional capacity due to flexion contractures of the adjacent joints. When calcinosis breaks the skin, ulcerative lesions develop with the possibility of bacterial superinfection.</p><p id="par0185" class="elsevierStylePara elsevierViewall">According to their origin, calcification of soft tissues can be classified into different variants: metastatic, dystrophic or idiopathic calciphylaxis. Dystrophic interests us in connection with scleroderma, because it originates in tissues affected by hypoxia caused by decreased perfusion and normal<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> mineral metabolism.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Diagnostic Aspects</span><p id="par0190" class="elsevierStylePara elsevierViewall">In the diagnosis of patients with Raynaud's phenomenon nailfold capillaroscopy is crucial, to separate those patients with primary Raynaud's phenomenon from patients with underlying connective tissue disease.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">The first diagnostic approach is achieved through interrogation: unlike patients with primary Raynaud, patients with secondary Raynaud's associated with connective tissue diseases have more severe attacks and are at risk for ischemic lesions with permanent tissue damage.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,6</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Nail bed capillaroscopy can be performed with 3 different instruments, depending on the resources available and the physician's prior training. It may be performed with a stereo binocular microscope which magnifies up to 40 times, with a videocapillaroscope, or a handheld digital microscope connected to a computer.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">Upon completion of capillaroscopy, office temperature should be 22–25<span class="elsevierStyleHsp" style=""></span>° C to avoid cold-induced Raynaud.</p><p id="par0210" class="elsevierStylePara elsevierViewall">Eight fingers should be examined, the second through the fifth fingers of each hand, and the most representative image or pattern is reported. Normal is defined as the presence of 9–11 capillaries aligned in a linear field of 1<span class="elsevierStyleHsp" style=""></span>mm, in the middle of the nailbed.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">The following changes must be described: hemorrhages, elongated megacapillaries, decreased number of capillaries, ramified capillaries and capillary disorganization of the nail vascular tree.</p><p id="par0220" class="elsevierStylePara elsevierViewall">In turn, in accordance with prevailing disturbances, 3 types of capillaroscopic patterns exist: early, active and late. In connection with the change from one pattern to another, it has been suggested that capillaroscopy be repeated every 6 months.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="par0225" class="elsevierStylePara elsevierViewall">Nailfold capillaroscopy will establish a qualitative pattern, a quantitative score and a predictive value index of the risk for ulcer development.<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22,23</span></a></p><p id="par0230" class="elsevierStylePara elsevierViewall">A validation has recently been published for the capillaroscopic index of risk for development of digital ulcers in scleroderma patients. This index allows, with high sensitivity, high specificity and high predictive value, to define those patients at high risk for developing digital ulcers within 3 months of the initial<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> capillaroscopy.</p><p id="par0235" class="elsevierStylePara elsevierViewall">Regardless of the possibility of the capillaroscopic risk index offering a high predictive value for developing digital ulcers with the simple observation of less than 4 capillaries per millimeter on the linear nail bed capillaroscopy, a history of ulcers is clinically more predictive and important for the development of new digital ulcers.<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22,23</span></a></p><p id="par0240" class="elsevierStylePara elsevierViewall">In patients without an established diagnosis of scleroderma, Raynaud's phenomenon, sclerodactyly and the presence of antinuclear antibodies are the so-called “red flags.”</p><p id="par0245" class="elsevierStylePara elsevierViewall">Those with those 3 red flags and a capillaroscopy suggestive of the disease and either the presence of autoantibodies, anticentromere or anti Scl70, constitute the subgroup of patients with so called early scleroderma (VEDOSS, very early diagnosis of systemic sclerosis).<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a></p><p id="par0250" class="elsevierStylePara elsevierViewall">The ability to diagnose the disease early will allow adequate and complete tracking of all other manifestations of scleroderma.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Therapeutic Aspects</span><p id="par0255" class="elsevierStylePara elsevierViewall">While both Raynaud, digital ulcers and calcinosis are clinical manifestations, there is no specific treatment is unique to scleroderma-like disease in itself. Treatments are aimed at the involvement of each organ or system in particular.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a></p><p id="par0260" class="elsevierStylePara elsevierViewall">When we talk about the therapeutic aspects, we must remember that uncontrolled or refractory Raynaud, especially that associated with connective tissue diseases, can lead to permanent tissue damage. On the other hand, in patients with digital ulcers or tissue damage already established, the goal is not only healing, but also preventing the development of new ulcers digitales.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,8,9</span></a></p><p id="par0265" class="elsevierStylePara elsevierViewall">The underlying calcinosis unresolved delay or prevent healing of digital ulcers.</p><p id="par0270" class="elsevierStylePara elsevierViewall">When defining each patient treatment should be instituted by a hand considering the indications according to technical specifications for the different drugs and, secondly, the proposed treatment based on the recommendations of various working groups, scientific societies, the published studies, some of them open, uncontrolled but significant number of patients included.</p><p id="par0275" class="elsevierStylePara elsevierViewall">By indicating the drug with higher levels of evidence, we must remember the difficulties reported in recruiting patients for clinical trials in scleroderma randomized controlled both by design errors as well due to the low prevalence of disease.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Treatment of Raynaud's Phenomenon</span><p id="par0280" class="elsevierStylePara elsevierViewall">The therapeutic approach to Raynaud's phenomenon depends, first, on whether it is primary or secondary. Patients with secondary Raynaud's have episodes that are more severe, frequent and prolonged. Under these conditions the presence of tissue ischemia defines the therapeutic behavior.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,6,7</span></a></p><p id="par0285" class="elsevierStylePara elsevierViewall">The drugs indicated are those designed to change reversible vasoconstriction. Patients with primary Raynaud's phenomenon have attacks of shorter duration and intensity and require, first, the correction of various triggering factors.</p><p id="par0290" class="elsevierStylePara elsevierViewall">Patients with Raynaud's phenomenon associated with scleroderma require drug treatment, and aggressive steps in relation to the lack of response.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Failure to respond will be defined by the persistence of the different phases of Raynaud despite appropriate treatment.</p><p id="par0295" class="elsevierStylePara elsevierViewall">In the treatment of Raynaud, calcium channel blockers are the first step in.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,25,26</span></a> Given the lack of response, drugs such as sildenafil may be added. Both iloprost and bosentan are reserved for refractory cases and critical tissue ischemia<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> and damage.</p><p id="par0300" class="elsevierStylePara elsevierViewall">Improvement has been measured in Raynaud's with thermography of the hands in patients treated with bosentan.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a></p><p id="par0305" class="elsevierStylePara elsevierViewall">In patients with scleroderma and non-digital ulcers, perilesional cyanosis as an expression of Raynaud and unresolved tissue damage can be considered as a predictor of good response in patients treated with bosentan.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p><p id="par0310" class="elsevierStylePara elsevierViewall">Other authors have also highlighted the importance of treatment of severe refractory Raynaud with bosentan.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">29–32</span></a></p><p id="par0315" class="elsevierStylePara elsevierViewall">Specifically, in terms of serious or severe Raynaud, with possible injury or development of ischemic tissue, various publications include algorithms and diagrams that provide a range of options ranging from general care to different drugs, and eventually hospitalization to initiate an infusion of prostacyclin and eventually perform a sympathectomy as an emergency measure.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,6,8,26</span></a></p><p id="par0320" class="elsevierStylePara elsevierViewall">When analyzing the schemes proposed for the treatment of severe Raynaud's, there are similarities with the various reports of reported treatment for the prevention and healing of digital sclerodermal ulcers.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,29–37</span></a></p><p id="par0325" class="elsevierStylePara elsevierViewall">In the presence of critical ischemia, or the lack of response, or causal, the involvement of major vessels, vasculitis or associated coagulopathy<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> should be considered also as a trigger.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Treatment of Digital Ulcers in Scleroderma</span><p id="par0330" class="elsevierStylePara elsevierViewall">Both prevention and treatment of digital ulcers in scleroderma patients is important to note as a parameter of response to treatment, both in the evolution of Raynaud as in pain of ischemic origin. If Raynaud and hence tissue ischemia is prolonged, or underlying calcinosis is not resolved, ulcers are difficult to cure and, once installed, tend to become chronic.</p><p id="par0335" class="elsevierStylePara elsevierViewall">The persistence of pain may be an expression not only ischemia but also superimposed infection.</p><p id="par0340" class="elsevierStylePara elsevierViewall">The drugs may be scaled as determined by each physician and in the order that the situation warrants, in accordance to the response.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6–9,25,26</span></a> Even for severe refractory cases the combination of them may be considered, but there is insufficient experience to endorse this.</p><p id="par0345" class="elsevierStylePara elsevierViewall">Regarding prevention and treatment of digital ulcers in scleroderma patients with active ulcers one must consider:<ul class="elsevierStyleList" id="lis0030"><li class="elsevierStyleListItem" id="lsti0150"><span class="elsevierStyleLabel">1.</span><p id="par0710" class="elsevierStylePara elsevierViewall">General measures.</p></li><li class="elsevierStyleListItem" id="lsti0155"><span class="elsevierStyleLabel">2.</span><p id="par0715" class="elsevierStylePara elsevierViewall">Pharmacological measures.</p></li><li class="elsevierStyleListItem" id="lsti0160"><span class="elsevierStyleLabel">3.</span><p id="par0720" class="elsevierStylePara elsevierViewall">Surgical options.</p></li></ul></p><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">General Measures</span><p id="par0365" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">-</span><p id="par0370" class="elsevierStylePara elsevierViewall">Define hospitalization criteria.</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">-</span><p id="par0375" class="elsevierStylePara elsevierViewall">Soothe pain, considering the need for the use of opiates.</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">-</span><p id="par0380" class="elsevierStylePara elsevierViewall">Warm the environment.</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">-</span><p id="par0385" class="elsevierStylePara elsevierViewall">Sedation: avoid stress, as this increases sympathetic tone, resulting in greater contraction.</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">-</span><p id="par0390" class="elsevierStylePara elsevierViewall">Check Raynaud periodically.</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">-</span><p id="par0395" class="elsevierStylePara elsevierViewall">Avoid contraceptives due to their prothrombotic action.</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">-</span><p id="par0400" class="elsevierStylePara elsevierViewall">Avoid coffee and tobacco.</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">-</span><p id="par0405" class="elsevierStylePara elsevierViewall">Avoid the use of vasoconstrictive drugs such as decongestants, amphetamines, ergotamine, etc.</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">-</span><p id="par0410" class="elsevierStylePara elsevierViewall">Avoid cold by wearing gloves.</p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">-</span><p id="par0415" class="elsevierStylePara elsevierViewall">Caring for the skin with the use of moisturizers on normal skin and handwashing with antiseptic soap.</p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">-</span><p id="par0420" class="elsevierStylePara elsevierViewall">Avoid repeated microtrauma of the hands.</p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">-</span><p id="par0425" class="elsevierStylePara elsevierViewall">Consider the possibility of bacterial infection and antibiotic treatment.</p></li><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">-</span><p id="par0430" class="elsevierStylePara elsevierViewall">Consider wide surgical removal of infected tissue, necrotic tissue or calcinosis in each particular case.</p></li><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">-</span><p id="par0435" class="elsevierStylePara elsevierViewall">Facilitate the healing of an ulcer with local treatment with vitamin E ointment.</p></li></ul></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Pharmacological Measures</span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Antiplatelet Drugs</span><p id="par0440" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">-</span><p id="par0445" class="elsevierStylePara elsevierViewall">Aspirin at an antiplatelet dose.</p></li><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">-</span><p id="par0450" class="elsevierStylePara elsevierViewall">Low molecular weight heparin (LMWH).</p></li></ul></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Vasodilators</span><p id="par0455" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">-</span><p id="par0460" class="elsevierStylePara elsevierViewall">Cilostazol.</p></li><li class="elsevierStyleListItem" id="lsti0105"><span class="elsevierStyleLabel">-</span><p id="par0465" class="elsevierStylePara elsevierViewall">Inhibitors of type 5 phosphodiesterase.</p></li><li class="elsevierStyleListItem" id="lsti0110"><span class="elsevierStyleLabel">-</span><p id="par0470" class="elsevierStylePara elsevierViewall">Calcium channel blockers.</p></li><li class="elsevierStyleListItem" id="lsti0115"><span class="elsevierStyleLabel">-</span><p id="par0475" class="elsevierStylePara elsevierViewall">Bosentan.</p></li><li class="elsevierStyleListItem" id="lsti0120"><span class="elsevierStyleLabel">-</span><p id="par0480" class="elsevierStylePara elsevierViewall">Prostacyclin analogues.</p></li></ul></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Other Drugs</span><p id="par0485" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0125"><span class="elsevierStyleLabel">-</span><p id="par0490" class="elsevierStylePara elsevierViewall">Serotonin receptor antagonists and reuptake inhibitors.</p></li><li class="elsevierStyleListItem" id="lsti0130"><span class="elsevierStyleLabel">-</span><p id="par0495" class="elsevierStylePara elsevierViewall">N-acetylcysteine.</p></li><li class="elsevierStyleListItem" id="lsti0135"><span class="elsevierStyleLabel">-</span><p id="par0500" class="elsevierStylePara elsevierViewall">Statins.</p></li><li class="elsevierStyleListItem" id="lsti0140"><span class="elsevierStyleLabel">-</span><p id="par0505" class="elsevierStylePara elsevierViewall">Botulinum toxin A.</p></li><li class="elsevierStyleListItem" id="lsti0145"><span class="elsevierStyleLabel">-</span><p id="par0510" class="elsevierStylePara elsevierViewall">Topical vitamin E gel.</p></li></ul></p></span></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Inpatient and Secondary Prevention of Thrombosis</span><p id="par0515" class="elsevierStylePara elsevierViewall">In the case of single or multiple digital ulcers we must consider the need for an outpatient clinic that facilitates medical management and quickly establish interdisciplinary and general measures.</p><p id="par0520" class="elsevierStylePara elsevierViewall">Laboratory assessments should include the search for a probable associated coagulopathy and tracking of including lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein antibodies.</p><p id="par0525" class="elsevierStylePara elsevierViewall">Eventually and in a preventive manner, consider LMWH to prevent secondary thrombosis in patients who are suffering from vasoconstriction and endothelial damage with greater tendency to platelet aggregation.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,38</span></a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Bosentan</span><p id="par0530" class="elsevierStylePara elsevierViewall">Several studies have reported the efficacy of bosentan for the prevention and treatment of digital ulcers in patients with active scleroderma.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,18,33–37,39</span></a></p><p id="par0535" class="elsevierStylePara elsevierViewall">According to technical data, bosentan is indicated for the treatment of pulmonary arterial hypertension (group I functional class II to IV) and for reducing the number of new digital ulcers in patients with systemic sclerosis (scleroderma) with ongoing disease.</p><p id="par0540" class="elsevierStylePara elsevierViewall">Bosentan is a dual antagonist of endothelin receptors. Blockade of endothelin receptors can be done in two ways: with greater selectivity for the A receptor, e.g. ambrisentan and sixtasentan (recalled due to liver toxicity), or in a dual form, blocking both the A and B receptors, which is the mechanism of action of bosentan.</p><p id="par0545" class="elsevierStylePara elsevierViewall">Clinical benefits of selective blockade vs dual blockade of endothelin are unknown. To date, bosentan is the only endothelin receptor antagonist approved for digital ulcers. Ambrisentan is only approved for pulmonary arterial hypertension.</p><p id="par0550" class="elsevierStylePara elsevierViewall">The efficacy of bosentan in the prevention of new digital ulcers has led to its approval was demonstrated in 2 randomized, double-blind, placebo-controlled multicentric trials.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,18</span></a> One study included patients with scleroderma who had a history of digital ulcers during the previous year but did not present active ulcers on inclusion, while the other study included subjects with active digital ulcer disease. Both studies evaluated prevention and healing of digital ulcers, differentiating ulcer healing on the one hand and all ulcers (old and new) on the other.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,18</span></a> These 2 studies show that bosentan achieved prevention in the development of new digital ulcers ranging from 30% (1.9 vs 2.7 new ulcers) to 48% (1.4 vs 2.7 new ulcers) of patients, according to whether patients had or did not have active ulcers at study entry, respectively. In the data related to healing in the group of patients with active ulcers at inclusion, ulcers healed in 50% of patients in both groups (bosentan group vs placebo group), while all digital ulcers (old and new combined) were cured in 36.8% of patients in the bosentan group and 39.3% of patients receiving placebo.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> These cure rates of both the cardinal ulcer, the old and new ulcers were similar for both groups, bosentan and placebo at 24 weeks.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> In this regard, it is important to analyze the demographics of the population included, because patients receiving various drugs with vasodilator action were found in both grupos.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,18</span></a> The reduction in the number of new digital ulcers (prevention) in patients treated with bosentan was more evident in the group of patients with 4 or more digital ulcers upon admission to the study.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="par0555" class="elsevierStylePara elsevierViewall">A retrospective multicenter open-label study done in Spain and published in 2011 analyzed the results obtained with bosentan in 67 patients with sclerodermal ulcers, followed at 12 and 24 months. The authors showed significant improvement of both active ulcers and in prevention of ulcers. The median time of treatment with bosentan was 13 months with a sustained efficacy follow-up. At the 12-month assessment (n=22), 81% had improved and 18.2% had stabilized ulcers. In terms of prevention, at 12 months, 68% of patients developed new ulcers.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a></p><p id="par0560" class="elsevierStylePara elsevierViewall">Anecdotally, we have reported an improvement in the skin score in patients treated with bosentan.<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">40,41</span></a> This could hypothetically contribute to the improvement of digital ulcers by reducing the induration of patients with scleroderma.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Calcium Channel Blockers</span><p id="par0565" class="elsevierStylePara elsevierViewall">Nifedipine and amlodipine are the most common: they reduce the intensity and frequency of Raynaud attacks. Calcium channel blockers are of limited use in general, due to poor efficacy and a high frequency of side effects: headache and lower limb edema. Doses should be scaled relative to the response and patient tolerance. Long-acting formulations are generally better tolerated.<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">42,43</span></a> They should be used with caution due to possible negative inotropic effects.</p><p id="par0570" class="elsevierStylePara elsevierViewall">In some reports, losartan had similar results or better than nifedipine.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Nitroglycerin Patches</span><p id="par0575" class="elsevierStylePara elsevierViewall">Transdermal nitroglycerin patches have been used in a small number of patients with good efficacy but with systemic effects such as headaches and hipotension.<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">45,46</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Inhibitors of Type 5 Phosphodiesterase</span><p id="par0580" class="elsevierStylePara elsevierViewall">Sildenafil and tadalafil are phosphodiesterase inhibitors that achieve vasodilation by increasing nitric oxide. These drugs have effects on both micro and macrovascular circulation.</p><p id="par0585" class="elsevierStylePara elsevierViewall">Sildenafil reduces Raynaud and, according to some studies, may be effective in promoting healing of digital ulcers. However, the doses required cause headache that limits their use. Efficacy has been evaluated both in clinical and imaging by determining Doppler digital flow or digital thermography in open studies or case reports.<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">47–50</span></a></p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Iloprost and Prostacyclin Analogues</span><p id="par0590" class="elsevierStylePara elsevierViewall">Iloprost and treprostinil have been used in trials with small numbers of patients and have been reported as effective for treating refractory Raynaud associated with scleroderma and the healing of digital ulcers.<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">51,52</span></a> They requires strict patient monitoring in hospital. A pump failure or catheter compression that suddenly stops the drip may produce death by drug rebound. Serious catheter related infections have also been reported.</p><p id="par0595" class="elsevierStylePara elsevierViewall">Another prostaglandin analog, alprostadil, administered intravenously 5 days in a row, has also been used in patients with refractory Raynaud.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a></p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Cilostazol</span><p id="par0600" class="elsevierStylePara elsevierViewall">Cilostazol is a selective inhibitor of phosphodiesterase III with antiplatelet and vasodilatory actions that can help improve blood flow, especially in patients with primary Raynaud and that associated with connective tissue disease.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a></p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Other Pharmacological Treatment Options</span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Serotonin Receptor Antagonists and Reuptake Inhibitors</span><p id="par0605" class="elsevierStylePara elsevierViewall">With respect to serotonin receptor antagonists and reuptake inhibitors, the information is contradictory. There has been improvement in Raynaud patients taking fluoxetine, sertraline and escitalopram, probably due to depletion of platelet serotonin.<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">55–57</span></a></p><p id="par0610" class="elsevierStylePara elsevierViewall">But, there are reports of worsening Raynaud's with these drugs, including digital<a class="elsevierStyleCrossRefs" href="#bib0290"><span class="elsevierStyleSup">58,59</span></a> necrosis.</p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">N-Acetylcysteine</span><p id="par0615" class="elsevierStylePara elsevierViewall">N-acetylcysteine intravenously has shown benefit in a small open study in patients with Raynaud's, scleroderma and digitales<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">60,61</span></a> ulcers.</p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Statins</span><p id="par0620" class="elsevierStylePara elsevierViewall">In a group of patients with Raynaud's and scleroderma, 40<span class="elsevierStyleHsp" style=""></span>mg of atorvastatin/day reduced the number of new ulcers compared with placebo (vasodilators), even changing endothelial<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">62</span></a> dysfunction markers.</p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Botulinum Toxin</span><p id="par0625" class="elsevierStylePara elsevierViewall">Occasionally, the interdigital injection of botulinum toxin, both in patients with primary and secondary Raynaud's may be beneficial.<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">63</span></a></p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Vitamin E Topical Gel</span><p id="par0630" class="elsevierStylePara elsevierViewall">Regarding local treatment, topical vitamin E gel may contribute to the improvement and healing of digital<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">64</span></a> ulcers.</p></span></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Surgical Options</span><p id="par0635" class="elsevierStylePara elsevierViewall">Chemical or surgical, cervical, thoracic or digital ultraselective sympathectomy may be considered as an emergency measure to achieve rapid vasodilation.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,6,8,26,65,66</span></a></p><p id="par0640" class="elsevierStylePara elsevierViewall">The beneficial effects observed in some patients may be transient. Please note also the possibility of postsurgical complications.<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">65</span></a></p><p id="par0645" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleInlineFigure"><elsevierMultimedia class="elsevierStyleLink" ident="fx1"></elsevierMultimedia></span></p><p id="par0650" class="elsevierStylePara elsevierViewall">Proposal for the prevention and treatment of digital ulcers in patients with scleroderma and active ulcers.</p><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Treatment of Calcinosis</span><p id="par0655" class="elsevierStylePara elsevierViewall">Regarding the treatment of calcinosis, no treatment is postulated to be more effective than another. Therapeutic alternatives include: warfarin, diltiazem, colchicine, probenecid, bisphosphonates, minocycline, aspirin, corticosteroid intralesional injections, aluminum hydroxide, IVIG, iontophoresis and ultrasound.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20,67,68</span></a></p><p id="par0660" class="elsevierStylePara elsevierViewall">Some authors suggest initiating therapy with diltiazem and even combining drugs.<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">67</span></a></p><p id="par0665" class="elsevierStylePara elsevierViewall">Importantly, the severity of calcinosis is not related to the severity of the underlying disease.<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">67</span></a></p><p id="par0670" class="elsevierStylePara elsevierViewall">Ulcerated calcinosis should be properly observed due to the possibility of bacterial superinfection.</p><p id="par0675" class="elsevierStylePara elsevierViewall">Surgical resolution may be considered in cases of extensive deposits of calcium that cause flexion contractures or impaired joint function but remembering that these injuries tend to become infected and are difficult to heal. For smaller localized lesions, CO<span class="elsevierStyleInf">2</span> laser and extracorporeal shock wave techniques can be useful.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20,67</span></a></p><p id="par0680" class="elsevierStylePara elsevierViewall">The case of a patient with scleroderma and extensive calcinosis complicated with skin infections who responded well to rituximab<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">68</span></a> has recently been reported.</p></span></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conclusions</span><p id="par0685" class="elsevierStylePara elsevierViewall">Raynaud's phenomenon, calcinosis and digital ulcers in scleroderma patients produce varying degrees of disability. Many patients present with ongoing ulcers in the clinic.</p><p id="par0690" class="elsevierStylePara elsevierViewall">It is important to exhaust all therapeutic instances, both those aimed at preventing the occurrence of new ulcers as those designed to achieve rapid healing before the permanent loss of tissue.</p><p id="par0695" class="elsevierStylePara elsevierViewall">To achieve the reversal of Raynaud's is the first step to avoid tissue ischemia.</p><p id="par0700" class="elsevierStylePara elsevierViewall">Calcinosis should be resolved in order to facilitate the healing of ulcerated lesions.</p></span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Ethical Responsibilities</span><p id="par0725" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Protection of Human and Animal Subjects</span>. The authors declare that no experiments were performed on humans or animals for this investigation.</p><p id="par0730" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Confidentiality of Data</span>. The authors declare that no patient data appear in this article.</p><p id="par0735" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Right to Privacy and Informed Consent</span>. The authors must have obtained the informed consent of the patients and /or subjects mentioned in the article. The author for correspondence must be in possession of this document.</p></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflict of Interest</span><p id="par0705" class="elsevierStylePara elsevierViewall">The author has no disclosures to make.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:24 [ 0 => array:2 [ "identificador" => "xres125931" "titulo" => "Abstract" ] 1 => array:2 [ "identificador" => "xpalclavsec113226" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres125932" "titulo" => "Resumen" ] 3 => array:2 [ "identificador" => "xpalclavsec113227" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Pathophysiology" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Clinical Manifestations" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Raynaud's Phenomenon" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Digital Ulcers in Scleroderma" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Calcinosis" ] ] ] 7 => array:2 [ "identificador" => "sec0035" "titulo" => "Diagnostic Aspects" ] 8 => array:2 [ "identificador" => "sec0040" "titulo" => "Therapeutic Aspects" ] 9 => array:2 [ "identificador" => "sec0045" "titulo" => "Treatment of Raynaud's Phenomenon" ] 10 => array:3 [ "identificador" => "sec0050" "titulo" => "Treatment of Digital Ulcers in Scleroderma" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0055" "titulo" => "General Measures" ] 1 => array:3 [ "identificador" => "sec0060" "titulo" => "Pharmacological Measures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "Antiplatelet Drugs" ] 1 => array:2 [ "identificador" => "sec0070" "titulo" => "Vasodilators" ] 2 => array:2 [ "identificador" => "sec0075" "titulo" => "Other Drugs" ] ] ] ] ] 11 => array:2 [ "identificador" => "sec0080" "titulo" => "Inpatient and Secondary Prevention of Thrombosis" ] 12 => array:2 [ "identificador" => "sec0085" "titulo" => "Bosentan" ] 13 => array:2 [ "identificador" => "sec0090" "titulo" => "Calcium Channel Blockers" ] 14 => array:2 [ "identificador" => "sec0095" "titulo" => "Nitroglycerin Patches" ] 15 => array:2 [ "identificador" => "sec0100" "titulo" => "Inhibitors of Type 5 Phosphodiesterase" ] 16 => array:2 [ "identificador" => "sec0105" "titulo" => "Iloprost and Prostacyclin Analogues" ] 17 => array:2 [ "identificador" => "sec0110" "titulo" => "Cilostazol" ] 18 => array:3 [ "identificador" => "sec0115" "titulo" => "Other Pharmacological Treatment Options" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0120" "titulo" => "Serotonin Receptor Antagonists and Reuptake Inhibitors" ] 1 => array:2 [ "identificador" => "sec0125" "titulo" => "N-Acetylcysteine" ] 2 => array:2 [ "identificador" => "sec0130" "titulo" => "Statins" ] 3 => array:2 [ "identificador" => "sec0135" "titulo" => "Botulinum Toxin" ] 4 => array:2 [ "identificador" => "sec0140" "titulo" => "Vitamin E Topical Gel" ] ] ] 19 => array:3 [ "identificador" => "sec0145" "titulo" => "Surgical Options" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0150" "titulo" => "Treatment of Calcinosis" ] ] ] 20 => array:2 [ "identificador" => "sec0155" "titulo" => "Conclusions" ] 21 => array:2 [ "identificador" => "sec0165" "titulo" => "Ethical Responsibilities" ] 22 => array:2 [ "identificador" => "sec0160" "titulo" => "Conflict of Interest" ] 23 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2011-12-26" "fechaAceptado" => "2012-02-29" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec113226" "palabras" => array:4 [ 0 => "Scleroderma" 1 => "Raynaud" 2 => "Digital ulcers" 3 => "Calcinosis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec113227" "palabras" => array:4 [ 0 => "Esclerodermia" 1 => "Raynaud" 2 => "Úlceras digitales" 3 => "Calcinosis" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Raynaud, digital ulcers and calcinosis are frequent manifestations of patients with systemic sclerosis. Digital ulcers are seen in more than half of the patients with scleroderma. Hospitalizations, ischemic complications and impairment of hand function are frequently observed in patients with digital ulcers, especially if treatment is delayed.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Rapid and intensive treatment escalation in patients with scleroderma and refractory Raynaud's phenomenon is one of the most effective preventive action available in order to avoid the development of digital ulcers and tissue loss.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">En pacientes con diagnóstico de esclerodermia, el fenómeno de Raynaud, las úlceras digitales y la calcinosis son manifestaciones frecuentes. Las úlceras digitales se observan en más de la mitad de los pacientes. El tratamiento tardío o las secuelas que generan las úlceras digitales con o sin calcinosis conllevan a un deterioro de la capacidad funcional de estos pacientes y complicaciones que pueden requerir hospitalización.</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">El tratamiento escalonado y temprano de los pacientes con esclerodermia y Raynaud refractario constituye la medida preventiva más efectiva para evitar el desarrollo de úlceras digitales y pérdida tisular.</p>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara">Please cite this article as: Nitsche A. Raynaud, úlceras digitales y calcinosis en esclerodermia. Reumatol Clin. 2012;8(5):270-7.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:68 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Hachulla" 1 => "P. Clerson" 2 => "D. Launay" 3 => "M. Lambert" 4 => "S. Morell-Dubois" 5 => "V. Queyrel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2007" "volumen" => "34" "paginaInicial" => "2423" "paginaFinal" => "2430" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17985402" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice. Raynaud's phenomenon" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F.M. Wigley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMcp013013" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2002" "volumen" => "347" "paginaInicial" => "1001" "paginaFinal" => "1008" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12324557" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Manual de capilaroscopía" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.L. Sormani de Fonseca" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2000" "editorial" => "Talleres Gráficos Alfa" "editorialLocalizacion" => "Buenos Aires" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reporting the recruitment process in clinical trials: who are these patients and how did they get there?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.P. Gross" 1 => "R. Mallory" 2 => "A. Heiat" 3 => "H.M. Krumholz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Inter Med" "fecha" => "2002" "volumen" => "137" "paginaInicial" => "10" "paginaFinal" => "16" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Canadian Scleroderma Research Group" "etal" => false "autores" => array:4 [ 0 => "R. Villela" 1 => "S.Y. Yuen" 2 => "J.E. Pope" 3 => "M. Baron" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23567" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "59" "paginaInicial" => "706" "paginaFinal" => "713" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18438906" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Contemporary management of Raynaud's phenomenon and digital ischaemic complications" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.L. Herrick" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0b013e32834aa40b" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Rheumatol" "fecha" => "2011" "volumen" => "23" "paginaInicial" => "555" "paginaFinal" => "561" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21885977" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment on healing and prevention of digital ulcers in systemic sclerosis (SSC): results from a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "T. Tingey" 1 => "J. Smucze" 2 => "J. Pope" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2011" "volumen" => "70" "numero" => "Suppl. 3" "paginaInicial" => "484" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Digital ulcers: overt vascular disease in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "V. Steen" 1 => "C.P. Denton" 2 => "J.E. Pope" 3 => "M. Matucci-Cerinic" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2009" "volumen" => "4" "numero" => "Suppl. 3" "paginaInicial" => "19" "paginaFinal" => "24" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Úlceras digitales en esclerosis sistémica" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Beltrán Catalán" 1 => "J.A. Román Ivorra" 2 => "J. Alegre Sancho" 3 => "I. Chalmeta Vedejo" 4 => "N. Fernández-Llanio Comella" 5 => "J. Ivorra Córtes" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Sem Fun Esp Reumatol" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "3" "paginaFinal" => "25" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mechanisms of disease. Scleroderma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Gabrielli" 1 => "E.V. Avvedimento" 2 => "T. Krieg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra0806188" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "360" "paginaInicial" => "1989" "paginaFinal" => "2003" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19420368" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sistema endotelina" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Baltazares Lipp" 1 => "H. Rodríguez Crespo" 2 => "J. Ortega Martínez" 3 => "A. Sotres-Vega" 4 => "M.E. Baltazares Lipp" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Inst Nal Enf Resp Mex" "fecha" => "2005" "volumen" => "18" "paginaInicial" => "308" "paginaFinal" => "320" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L.E. Spieker" 1 => "G. Noll" 2 => "F.T. Ruschitzka" 3 => "T.F. Lüscher" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2001" "volumen" => "37" "paginaInicial" => "1493" "paginaFinal" => "1505" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11345356" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673611603255" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T.F. Lüscher" 1 => "M. Barton" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2000" "volumen" => "102" "paginaInicial" => "2434" "paginaFinal" => "2440" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11067800" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Significance of plasma endothelin-1 levels in patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Yamane" 1 => "T. Miyauchi" 2 => "N. Suzuki" 3 => "T. Yuhara" 4 => "T. Akama" 5 => "H. Suzuki" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "1992" "volumen" => "19" "paginaInicial" => "1566" "paginaFinal" => "1571" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1464869" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis associated pulmonary hypertension: improved survival in the current era" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.H. Williams" 1 => "C. Das" 2 => "C.E. Handler" 3 => "M.R. Akram" 4 => "J. Davar" 5 => "C.P. Denton" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/hrt.2005.069484" "Revista" => array:6 [ "tituloSerie" => "Heart" "fecha" => "2006" "volumen" => "92" "paginaInicial" => "926" "paginaFinal" => "932" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16339813" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 lesions" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Amanzi" 1 => "F. Braschi" 2 => "G. Fiori" 3 => "F. Galluccio" 4 => "I. Miniati" 5 => "S. Giudicci" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/keq097" "Revista" => array:6 [ "tituloSerie" => "Rheumatology" "fecha" => "2010" "volumen" => "49" "paginaInicial" => "1374" "paginaFinal" => "1382" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20400463" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.H. Korn" 1 => "M. Mayes" 2 => "M. Matucci Cerinic" 3 => "M. Rainisio" 4 => "J. Pope" 5 => "E. Hachulla" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.20676" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2004" "volumen" => "50" "paginaInicial" => "3985" "paginaFinal" => "3993" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15593188" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Matucci-Cerinic" 1 => "C.P. Denton" 2 => "D.E. Furst" 3 => "M.D. Mayes" 4 => "V.M. Hsu" 5 => "P. Carpentier" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2010.130658" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2011" "volumen" => "70" "paginaInicial" => "32" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20805294" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis: outcome and long term follow-up of 429 pactients from a single Italian centre" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Doveri" 1 => "A. Della Rossa" 2 => "S. Salvadori" 3 => "A. D Ascanio" 4 => "A. Tavoni" 5 => "L. Bazzichi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2010.139196" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2011" "volumen" => "70" "numero" => "Suppl. 3" "paginaInicial" => "660" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21187297" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Calcinosis in rheumatic diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "N. Boulman" 1 => "G. Slobodin" 2 => "M. Rozenbaum" 3 => "I. Rosner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2005.01.016" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2005" "volumen" => "34" "paginaInicial" => "805" "paginaFinal" => "812" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15942915" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transition from early to late pattern of nailfold microangiopathy in systemic sclerosis: a quick event to be strictly monitored" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Sulli" 1 => "C. Pizzorni" 2 => "G. Zampogna" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2011" "volumen" => "70" "numero" => "Suppl. 3" "paginaInicial" => "475" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Scoring the capillaroscopic images: which hallmark parameters should be scored" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Sulli" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2011" "volumen" => "70" "numero" => "Suppl. 3" "paginaInicial" => "23" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Sebastiani" 1 => "A. Manfredi" 2 => "G. Vukatana" 3 => "S. Mosactelli" 4 => "L. Riato" 5 => "M. Bocci" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2011-200022" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2012" "volumen" => "71" "paginaInicial" => "67" "paginaFinal" => "70" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21917823" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Avouac" 1 => "J. Fransen" 2 => "U.A. Walker" 3 => "V. Riccieri" 4 => "V. Smith" 5 => "C. Muller" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2010.136929" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2011" "volumen" => "70" "paginaInicial" => "476" "paginaFinal" => "481" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21081523" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Kowal-Bielecka" 1 => "R. Landewé" 2 => "J. Avouac" 3 => "S. Chwiesko" 4 => "I. Miniati" 5 => "L. Czirjak" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2008.096677" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2009" "volumen" => "68" "paginaInicial" => "620" "paginaFinal" => "628" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19147617" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento del fenómeno de Raynaud" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "V. Fonollosa-Pla" 1 => "C.P. Simeón-Aznar" 2 => "M. Vilardell-Tarrés" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Clin Esp" "fecha" => "2009" "volumen" => "209" "paginaInicial" => "21" "paginaFinal" => "24" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19268093" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Rosato" 1 => "I. Molinaro" 2 => "F. Borghese" 3 => "C. Rossi" 4 => "S. Pisarri" 5 => "F. Salsano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.100358" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2010" "volumen" => "37" "paginaInicial" => "2531" "paginaFinal" => "2539" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20810512" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of bosentan on non digital ulcers in patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Taniguchi" 1 => "Y. Asano" 2 => "M. Hatano" 3 => "Z. Tamaki" 4 => "M. Tomita" 5 => "T. Kawashima" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2011.10581.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2012" "volumen" => "166" "paginaInicial" => "417" "paginaFinal" => "421" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21848685" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N. Selenko-Gebauer" 1 => "N. Duschek" 2 => "G. Minimair" 3 => "G. Stingl" 4 => "F. Karlhofer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2006" "volumen" => "45" "numero" => "Suppl. 3" "paginaInicial" => "iii45" "paginaFinal" => "iii48" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.E. Hettema" 1 => "D. Zhang" 2 => "H. Bootsma" 3 => "C.G. Kallenberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2007.073684" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2007" "volumen" => "66" "paginaInicial" => "1398" "paginaFinal" => "1399" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17881663" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Ramos-Casals" 1 => "P. Brito-Zerón" 2 => "N. Nardi" 3 => "G. Claver" 4 => "G. Risco" 5 => "F.D. Parraga" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2004" "volumen" => "43" "paginaInicial" => "1454" "paginaFinal" => "1456" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Dunne" 1 => "J. Dutz" 2 => "K. Shojania" 3 => "B. Ng" 4 => "S. Van Eeden" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2006" "volumen" => "45" "paginaInicial" => "911" "paginaFinal" => "912" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.R. Seibold" 1 => "M. Matucci-Cerinic" 2 => "C.P. Denton" 3 => "D.E. Furst" 4 => "M.D. Mayes" 5 => "F. Kramer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2006" "volumen" => "65" "numero" => "Suppl. II" "paginaInicial" => "90" ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. García de la Peña-Lefebvre" 1 => "S. Rodríguez Rubio" 2 => "M. Valero Expósito" 3 => "L. Carmona" 4 => "M.L. Gámir Gámir" 5 => "J. Beltrán Gutiérrez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "464" "paginaFinal" => "466" ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bosentan for treatment of active digital ulcers in patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Launay" 1 => "E. Diot" 2 => "E. Pasquier" 3 => "L. Mouthon" 4 => "N. Boullanger" 5 => "O. Fain" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Presse Med" "fecha" => "2006" "volumen" => "35" "numero" => "4 Pt 1" "paginaInicial" => "587" "paginaFinal" => "592" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16614599" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "T.L. Moore" 1 => "A. Vail" 2 => "A.L. Herrick" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "363" "paginaFinal" => "364" ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.P. Sfikakis" 1 => "C. Papamichael" 2 => "K.S. Stamatelopoulos" 3 => "D. Tousoulis" 4 => "K.G. Fragiadaki" 5 => "P. Katsichti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.22634" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2007" "volumen" => "56" "paginaInicial" => "1985" "paginaFinal" => "1993" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17530638" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.P. Denton" 1 => "K. Howell" 2 => "R.J. Stratton" 3 => "C.M. Black" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2000" "volumen" => "18" "paginaInicial" => "499" "paginaFinal" => "502" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10949727" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.A. Roman Ivorra" 1 => "C.P. Simeon" 2 => "J.J. Alegre Sancho" 3 => "M.V. Egurbide" 4 => "M.J. Castillo" 5 => "X. Lloria" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.101266" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2011" "volumen" => "38" "paginaInicial" => "1631" "paginaFinal" => "1635" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21632679" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Kuhn" 1 => "M. Haust" 2 => "V. Ruland" 3 => "R. Weber" 4 => "P. Verde" 5 => "G. Felder" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2010" "volumen" => "49" "paginaInicial" => "1336" "paginaFinal" => "1345" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of bosentan on the skin lesions: an observational study from a single center in Japan" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Funauchi" 1 => "K. Kishimoto" 2 => "H. Shimazu" 3 => "Y. Nagare" 4 => "S. Hino" 5 => "T. Yano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-008-0789-z" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2009" "volumen" => "29" "paginaInicial" => "769" "paginaFinal" => "775" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19037604" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.E. Thompson" 1 => "J.E. Pope" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2005" "volumen" => "44" "paginaInicial" => "145" "paginaFinal" => "150" ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral vasodilators for primary Raynaud's phenomenon" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Vinjar" 1 => "M. Stewart" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2008" "volumen" => "16" "paginaInicial" => "CD006687" ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Dziadzio" 1 => "C.P. Denton" 2 => "R. Smith" 3 => "K. Howell" 4 => "A. Blann" 5 => "E. Bowers" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "1999" "volumen" => "42" "paginaInicial" => "2646" "paginaFinal" => "2655" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10616013" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.G. Franks Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "1982" "volumen" => "1" "paginaInicial" => "76" "paginaFinal" => "77" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2891981" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L.S. Teh" 1 => "J. Manning" 2 => "T. Moore" 3 => "M.P. Tully" 4 => "D. O’Reilly" 5 => "M.I. Jayson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Rheumatol" "fecha" => "1995" "volumen" => "34" "paginaInicial" => "636" "paginaFinal" => "641" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7670782" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Caglayan" 1 => "M. Huntgeburth" 2 => "T. Karasch" 3 => "J. Weihrauch" 4 => "N. Hunzelmann" 5 => "T. Krieg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archinte.166.2.231" "Revista" => array:6 [ "tituloSerie" => "Arch Intern Med" "fecha" => "2006" "volumen" => "166" "paginaInicial" => "231" "paginaFinal" => "233" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16432094" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Kumar" 1 => "B. Griffiths" 2 => "J. Allen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "1918" "paginaFinal" => "1919" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16960964" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.S. Brueckner" 1 => "M.O. Becker" 2 => "T. Kroencke" 3 => "D. Huscher" 4 => "H.U. Scherer" 5 => "M. Worm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.116475" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "1475" "paginaFinal" => "1478" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19900936" "web" => "Medline" ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phosphodiesrerase-5 inhibitors for the treatment of Raynaud's: a novel indication" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.J. De LaVega" 1 => "C.T. Derk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/13543780802525100" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Investig Drugs" "fecha" => "2009" "volumen" => "18" "paginaInicial" => "23" "paginaFinal" => "29" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19053879" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.J. García Hernández" 1 => "C. Ocaña Medina" 2 => "L. Mateos Romero" 3 => "J. Molinillo López" 4 => "A. Arias Zambrano" 5 => "R. González León" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2004" "volumen" => "122" "paginaInicial" => "501" "paginaFinal" => "504" ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treprostinil for the treatment of severe digital necrosis in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E. Engel" 1 => "S. Rockson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Vasc Med" "fecha" => "2005" "volumen" => "10" "paginaInicial" => "29" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15920997" "web" => "Medline" ] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of severe Raynaud's phenomenon in collagen diseases with alprostadil IV" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Beltrán" 1 => "C. Pérez García" 2 => "J. Blanch" 3 => "A. Toll" 4 => "N. Segales" 5 => "I. Prado" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2005" "volumen" => "64" "numero" => "Suppl. III" "paginaInicial" => "S304" ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of cilostazol in patients with Raynaud's syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Rajagopalan" 1 => "D. Pfenninger" 2 => "E. Somers" 3 => "C. Kehrer" 4 => "A. Chakrabarti" 5 => "D. Mukherjee" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Cardiol" "fecha" => "2003" "volumen" => "92" "paginaInicial" => "1310" "paginaFinal" => "1315" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14636909" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Rey" 1 => "E. Cretel" 2 => "R. Jean" 3 => "M.J. Pastor" 4 => "J.M. Durand" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rheumatology" "fecha" => "2003" "volumen" => "42" "paginaInicial" => "601" "paginaFinal" => "602" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12649412" "web" => "Medline" ] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of Raynaud's phenomenon with escitalopram" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Buecking" 1 => "E. Rougemont" 2 => "D.F. Zullino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1017/S1461145704004882" "Revista" => array:6 [ "tituloSerie" => "Int J Neuropsychopharmacol" "fecha" => "2005" "volumen" => "8" "paginaInicial" => "307" "paginaFinal" => "308" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15569398" "web" => "Medline" ] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Coleiro" 1 => "S.E. Marshall" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rheumatology" "fecha" => "2001" "volumen" => "40" "paginaInicial" => "1038" "paginaFinal" => "1043" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11561116" "web" => "Medline" ] ] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Digital infarction in a patient with Raynaud's phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Bell" 1 => "N. Coupland" 2 => "P. Creamer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Angiology" "fecha" => "1996" "volumen" => "47" "paginaInicial" => "901" "paginaFinal" => "903" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8810657" "web" => "Medline" ] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Citalopram-induced Raynaud's phenomenon" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.M. Peiró" 1 => "C. Margarit" 2 => "M. Torra" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-006-0254-9" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2007" "volumen" => "27" "paginaInicial" => "599" "paginaFinal" => "601" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17103176" "web" => "Medline" ] ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0300" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Sambo" 1 => "D. Amico" 2 => "R. Giacomelli" 3 => "M. Matucci-Cerinic" 4 => "F. Salsano" 5 => "G. Valentini" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2001" "volumen" => "28" "paginaInicial" => "2257" "paginaFinal" => "2262" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11669166" "web" => "Medline" ] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0305" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Salsano" 1 => "C. Letizia" 2 => "M. Proietti" 3 => "C. Rossi" 4 => "A.R. Proietti" 5 => "E. Rosato" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Immunopathol Pharmacol" "fecha" => "2005" "volumen" => "18" "paginaInicial" => "761" "paginaFinal" => "770" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16388726" "web" => "Medline" ] ] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0310" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Abou-Raya" 1 => "S. Abou-Raya" 2 => "M. Helmii" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2008" "volumen" => "35" "paginaInicial" => "1801" "paginaFinal" => "1808" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18709692" "web" => "Medline" ] ] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0315" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Fregene" 1 => "D. Ditmars" 2 => "A. Siddiqui" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Hand Surg" "fecha" => "2009" "volumen" => "34A" "paginaInicial" => "446" "paginaFinal" => "452" ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0320" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Fiori" 1 => "F. Galluccio" 2 => "F. Braschi" 3 => "L. Amanzi" 4 => "I. Miniati" 5 => "M.L. Conforti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2009" "volumen" => "27" "numero" => "3 Suppl. 54" "paginaInicial" => "51" "paginaFinal" => "54" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19796562" "web" => "Medline" ] ] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0325" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.V. Kotsis" 1 => "K.C. Chung" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2003" "volumen" => "30" "paginaInicial" => "1788" "paginaFinal" => "1792" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12913936" "web" => "Medline" ] ] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0330" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thoracic sympathectomy for digital ischemia: a summary of evidence" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "H.M. Coveliers" 1 => "F. Hoexum" 2 => "J.H. Nederhoed" 3 => "W. Wisselink" 4 => "J.A. Rauwerda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jvs.2011.01.069" "Revista" => array:6 [ "tituloSerie" => "J Vasc Surg" "fecha" => "2011" "volumen" => "54" "paginaInicial" => "273" "paginaFinal" => "277" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21652164" "web" => "Medline" ] ] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0335" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Calcinosis cutis occurring in association with autoimmune connective tissue disease. The Mayo Clinic Experience with 78 patients, 1996–2009" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S.J. Balin" 1 => "D.A. Wetter" 2 => "L.K. Andersen" 3 => "M.D. Davis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2012" "volumen" => "184" "paginaInicial" => "455" "paginaFinal" => "462" ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0340" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D. Daoussis" 1 => "I. Antonopoulos" 2 => "S.N. Liossis" 3 => "G. Yiannopoulos" 4 => "A.P. Andonopoulos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2011.11.007" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2012" "volumen" => "41" "paginaInicial" => "822" "paginaFinal" => "829" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22221908" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000000800000005/v1_201305061645/S2173574312001323/v1_201305061645/en/main.assets" "Apartado" => array:4 [ "identificador" => "8383" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000000800000005/v1_201305061645/S2173574312001323/v1_201305061645/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574312001323?idApp=UINPBA00004M" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 October | 197 | 51 | 248 |
2024 September | 201 | 38 | 239 |
2024 August | 243 | 53 | 296 |
2024 July | 360 | 63 | 423 |
2024 June | 320 | 49 | 369 |
2024 May | 309 | 62 | 371 |
2024 April | 281 | 39 | 320 |
2024 March | 2204 | 53 | 2257 |
2024 February | 205 | 44 | 249 |
2024 January | 252 | 33 | 285 |
2023 December | 177 | 28 | 205 |
2023 November | 203 | 53 | 256 |
2023 October | 377 | 40 | 417 |
2023 September | 405 | 71 | 476 |
2023 August | 314 | 51 | 365 |
2023 July | 247 | 56 | 303 |
2023 June | 231 | 43 | 274 |
2023 May | 206 | 39 | 245 |
2023 April | 329 | 40 | 369 |
2023 March | 500 | 56 | 556 |
2023 February | 401 | 54 | 455 |
2023 January | 369 | 34 | 403 |
2022 December | 311 | 57 | 368 |
2022 November | 344 | 39 | 383 |
2022 October | 302 | 71 | 373 |
2022 September | 362 | 63 | 425 |
2022 August | 276 | 49 | 325 |
2022 July | 371 | 56 | 427 |
2022 June | 268 | 74 | 342 |
2022 May | 415 | 75 | 490 |
2022 April | 590 | 84 | 674 |
2022 March | 562 | 85 | 647 |
2022 February | 525 | 75 | 600 |
2022 January | 400 | 69 | 469 |
2021 December | 253 | 93 | 346 |
2021 November | 193 | 74 | 267 |
2021 October | 239 | 79 | 318 |
2021 September | 278 | 70 | 348 |
2021 August | 145 | 54 | 199 |
2021 July | 186 | 36 | 222 |
2021 June | 139 | 48 | 187 |
2021 May | 129 | 62 | 191 |
2021 April | 268 | 155 | 423 |
2021 March | 167 | 73 | 240 |
2021 February | 138 | 31 | 169 |
2021 January | 163 | 30 | 193 |
2020 December | 151 | 36 | 187 |
2020 November | 135 | 30 | 165 |
2020 October | 92 | 20 | 112 |
2020 September | 108 | 55 | 163 |
2020 August | 152 | 37 | 189 |
2020 July | 90 | 27 | 117 |
2020 June | 81 | 38 | 119 |
2020 May | 79 | 18 | 97 |
2020 April | 71 | 31 | 102 |
2020 March | 40 | 11 | 51 |
2020 January | 4 | 0 | 4 |
2019 September | 4 | 0 | 4 |
2019 June | 1 | 0 | 1 |
2019 March | 1 | 0 | 1 |
2019 January | 1 | 0 | 1 |
2018 May | 25 | 0 | 25 |
2018 April | 182 | 27 | 209 |
2018 March | 223 | 18 | 241 |
2018 February | 282 | 25 | 307 |
2018 January | 268 | 25 | 293 |
2017 December | 265 | 28 | 293 |
2017 November | 319 | 24 | 343 |
2017 October | 353 | 21 | 374 |
2017 September | 216 | 27 | 243 |
2017 August | 227 | 26 | 253 |
2017 July | 254 | 22 | 276 |
2017 June | 274 | 39 | 313 |
2017 May | 439 | 27 | 466 |
2017 April | 538 | 19 | 557 |
2017 March | 530 | 28 | 558 |
2017 February | 679 | 27 | 706 |
2017 January | 450 | 25 | 475 |
2016 December | 574 | 23 | 597 |
2016 November | 592 | 26 | 618 |
2016 October | 644 | 25 | 669 |
2016 September | 913 | 27 | 940 |
2016 August | 768 | 13 | 781 |
2016 July | 472 | 27 | 499 |
2016 June | 1 | 0 | 1 |
2016 May | 2 | 0 | 2 |
2015 December | 2 | 0 | 2 |
2015 November | 2 | 52 | 54 |
2015 October | 6 | 64 | 70 |
2015 September | 1 | 0 | 1 |
2015 August | 1 | 0 | 1 |
2015 July | 420 | 16 | 436 |
2015 June | 851 | 19 | 870 |
2015 May | 960 | 30 | 990 |
2015 April | 1203 | 30 | 1233 |
2015 March | 1378 | 22 | 1400 |
2015 February | 1067 | 10 | 1077 |
2015 January | 1018 | 16 | 1034 |
2014 December | 981 | 16 | 997 |
2014 November | 1232 | 20 | 1252 |
2014 October | 684 | 14 | 698 |
2014 September | 528 | 20 | 548 |
2014 August | 521 | 26 | 547 |
2014 July | 586 | 16 | 602 |
2014 June | 692 | 31 | 723 |
2014 May | 563 | 17 | 580 |
2014 April | 574 | 13 | 587 |
2014 March | 499 | 27 | 526 |
2014 February | 463 | 31 | 494 |
2014 January | 432 | 24 | 456 |
2013 December | 372 | 16 | 388 |
2013 November | 362 | 28 | 390 |
2013 October | 347 | 23 | 370 |
2013 September | 291 | 17 | 308 |
2013 August | 327 | 21 | 348 |
2013 July | 275 | 31 | 306 |
2013 June | 352 | 25 | 377 |
2013 May | 321 | 35 | 356 |
2013 April | 238 | 46 | 284 |
2013 March | 129 | 33 | 162 |
2013 February | 123 | 22 | 145 |
2013 January | 94 | 15 | 109 |
2012 December | 62 | 36 | 98 |
2012 November | 80 | 42 | 122 |
2012 October | 58 | 33 | 91 |